Evidence map›Paper›PMID 17485251›Full record

ArticleDNA repair2007

Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Ryan J Hansen, Susan M Ludeman, Sari J Paikoff, Anthony E Pegg, M Eileen Dolan

Open access · greenAbstract read
In one paragraph

Article in DNA repair, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. New insights into estrogenic regulation ofJournal of biomedical research · 2016
    Article
  5. Article
  6. Article
  7. OOncology letters · 2014
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ryan J HansenCommittee on Cancer Biology, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
Susan M Ludeman
Sari J Paikoff
Anthony E Pegg
M Eileen Dolan
Duke Medical Center · USPennsylvania State University · USUniversity of Chicago · US

Funding

Multi-Disciplinary Training Grant in Cancer ResearchT32CA009594 · NCI · UNIVERSITY OF CHICAGO · PI KAY F MACLEOD, Scott A. Oakes · 1989 to 2026
$11.5M
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALYKLATORSR01CA016783 · NCI · JOHNS HOPKINS UNIVERSITY · PI LUDEMAN, SUSAN M · 1985 to 2009
$2.8M
PERSISTENCE OF ALKYLATED DNA IN CARCINOGENESISR01CA018137 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KANUGULA, SREENIVAS · 1985 to 2011
$2.8M
ALKYLTRANSFERASE INHIBITORS FOR CANCER CHEMOTHERAPYR01CA071976 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KANUGULA, SREENIVAS · 1996 to 2010
$2.7M
Role of DNA In Protecting Against Secondary LeukemiasR01CA081485 · NCI · UNIVERSITY OF CHICAGO · PI DOLAN, MARY EILEEN · 1999 to 2008
$1.9M
PERSISTENCE OF ALKYLATED DNA IN CARCINOGENESISR37CA018137 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI PEGG, ANTHONY E · 1989 to 2009
$972k
TRAINING PROGRAM IN ENVIRONMENTAL BIOLOGY (NRSA)T32CA009273 · NCI · UNIVERSITY OF CHICAGO · PI WEICHSELBAUM, RALPH R · 1985 to 2000
$135k
NCI NIH HHS 5T32 CA09273NCI NIH HHS 5T32 CA09594NCI NIH HHS CA016783NCI NIH HHS CA018137NCI NIH HHS CA071976NCI NIH HHS CA081485NCI NIH HHS R01 CA016783NCI NIH HHS R01 CA018137NCI NIH HHS R01 CA071976NCI NIH HHS R01 CA081485NCI NIH HHS R37 CA018137NCI NIH HHS T32 CA009273NCI NIH HHS T32 CA009594
6 · The paper itself

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that protects cells from the biological consequences of alkylating agents by removing alkyl groups from the O(6)-position of guanine. Cyclophosphamide and ifosfamide are oxazaphosphorines used clinically to treat a wide variety of cancers; however, the role of MGMT in recognizing DNA damage induced by these agents is unclear. In vitro evidence suggests that MGMT may protect against the urotoxic oxazaphosphorine metabolite, acrolein. Here, we demonstrate that Chinese hamster ovary cells transfected with MGMT are protected against cytotoxicity following treatment with chloroacetaldehyde (CAA), a neuro- and nephrotoxic metabolite of cyclophosphamide and ifosfamide. The mechanism by which MGMT recognizes damage induced by acrolein and CAA is unknown. CHO cells expressing a mutant form of MGMT (MGMT(R128A)), known to have >1000-fold less repair activity towards alkylated DNA while maintaining full active site transferase activity towards low molecular weight substrates, exhibited equivalent CAA- and acrolein-induced cytotoxicity to that of CHO cells transfected with plasmid control. These results imply that direct reaction of acrolein or CAA with the active site cysteine residue of MGMT, i.e. scavenging, is unlikely a mechanism to explain MGMT protection from CAA and acrolein-induced toxicity. In vivo, no difference was detected between Mgmt-/- and Mgmt+/+ mice in the lethal effects of cyclophosphamide. While MGMT may be important at the cellular level, mice deficient in MGMT are not significantly more susceptible to cyclophosphamide, acrolein or CAA. Thus, our data does not support targeting MGMT to improve oxazaphosphorine therapy.

Indexed as

AcetaldehydeAcroleinAlkylating AgentsAnimalsCHO CellsCricetinaeCricetulusCyclophosphamideDNA RepairDrug Resistance, NeoplasmIfosfamideMiceMice, KnockoutMutationNeoplasms, ExperimentalO(6)-Methylguanine-DNA MethyltransferaseAcetaldehydeAcroleinAlkylating AgentschloroacetaldehydeCyclophosphamideIfosfamideO(6)-Methylguanine-DNA MethyltransferaseRecombinant Proteins

Identifiers

PMID17485251
PMCPMC1989758
OpenAlexW2047673434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.